B+
Bull case
25%
Probability
Target price
$6.80
Analysis reference price unavailable
Analysis 2026-11-04 · RankAlpha Sentiment Codex
PMN
ProMIS NeurosciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 company release reported no ARIA-E among 136 safety-evaluable PRECISE-AD participants and $53.4 million in cash and short-term investments at June 30, with management expecting runway through 2027. Favorable unblinded safety and cognitive results could materially improve the thesis.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-11-10.
What can break
Blinded, pooled interim biomarker movements cannot establish PMN310 efficacy versus placebo. [#SEC-8K-2026-08-13]
Momentum
96
Value
58
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.00 · Bull $6.80 · Bear $1.20Analysis 2026-11-04; returns require an exact persisted reference.
Earnings
2026-11-10
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-03 • Vendor: Data Vendor v1
Scores
As of 2026-11-04 • Model: HYBRID_IC_RP
AI Memo
As of 2026-11-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-11-04
Investment thesis
As of 2026-11-04
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-04. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $42.58
Why
Momentum96 · Δ7d -
Value58 · Δ7d +16.9
Sentiment53 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-10.
- • Value remains the lead driver in the composite, 7D delta +16.9.
Contradictions & invalidation
- • Blinded, pooled interim biomarker movements cannot establish PMN310 efficacy versus placebo. [#SEC-8K-2026-08-13]
- • June 30 cash and the stated runway through 2027 may change with R&D spending or financing. [#SEC-8K-2026-08-13]
- • The interim biomarker analysis pooled active and placebo patients while the trial remained blinded.
Catalyst clock
2026-11-10
PRECISE-AD 12-month dosing completion
Lead driver: Value · See fundamentals
Momentum
96
18% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
43% active weight
Current posture
7d trendImproving
Δ7d
+16.9
Δ21d
+16.7
Sentiment
53
39% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 95.8 / Value 57.5 / Sentiment 53.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-11-04. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-11-04 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-11-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-11-03
Fundamentals (TTM)
As of 2026-11-03
Market Cap
$30.58M
Beta
-0.09
Shares Out
8.97M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.27
Rev YoY
-100.0%
EPS YoY
-82.3%
Gross Margin
-
Op Margin
-
Net Debt
-$6.15M
Current Ratio
7.85
As of 2026-11-04 • Updated nightlySource: Internal modelMethods & Data